Lennox–Gastaut syndrome

Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer

Retrieved on: 
Wednesday, June 1, 2022

"We are pleased to be included in these key epilepsy conferences this summer.

Key Points: 
  • "We are pleased to be included in these key epilepsy conferences this summer.
  • LP352 is designed to modulate GABA and, as a result, suppress the central hyperexcitability that is characteristic of seizures.
  • Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Aquestive Therapeutics Announces CEO Transition

Retrieved on: 
Tuesday, May 17, 2022

Under the terms of the consulting agreement, Mr. Kendall will assist in the transition of the role of CEO and the execution of the Companys business strategy and operations until the end of the year.

Key Points: 
  • Under the terms of the consulting agreement, Mr. Kendall will assist in the transition of the role of CEO and the execution of the Companys business strategy and operations until the end of the year.
  • Mr. Costa stated, The Board is excited to have Dan join the board and expand his responsibilities at Aquestive.
  • Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients problems with current standards of care and provide transformative products to improve their lives.
  • PharmFilm, Sympazan and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2022.
  • Its been a productive year thus far as we prepare for our first commercial launch and make important advancements across our clinical programs.
  • At March 31, 2022, the company had cash and cash equivalents of $126.3 million, compared to $122.9 million at December 31, 2021.
  • Marinus recognized $14.2 million in revenue for the three months ended March 31, 2022, as compared to $1.8 million for the three months ended March 31, 2021.

Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Tuesday, May 10, 2022

Ovid expects to file an IND for OV329 and initiate Phase 1 trials in the fourth quarter of 2022.

Key Points: 
  • Ovid expects to file an IND for OV329 and initiate Phase 1 trials in the fourth quarter of 2022.
  • Data supporting the preclinical efficacy and safety profile of OV329 are expected to be presented at epilepsy research meetings in the second quarter of 2022.
  • Revenue for the first quarter ended March31, 2022 was $1.4 million, as compared to $208.4 million for the same period in 2021.
  • Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science.

Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 10, 2022

WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the H.C. Wainwright Global Investment Conference from May 23rd to May 26th.

Key Points: 
  • WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the H.C. Wainwright Global Investment Conference from May 23rd to May 26th.
  • The Aquestive team is scheduled to present on May 25th at 2:30 pm ET and will host investor meetings at the conference through May 26th.
  • Aquestive Therapeutics, Inc.(NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients problems with current standards of care and provide transformative products to improve their lives.
  • PharmFilm, Sympazan and the Aquestive logo are registered trademarks ofAquestive Therapeutics, Inc.

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022

LP659, an oral, selective, centrally acting S1P receptor modulator targeting multiple neurological diseases, is currently in IND-enabling studies with IND application submission to the FDA expected in the fourth quarter of 2022.

Key Points: 
  • LP659, an oral, selective, centrally acting S1P receptor modulator targeting multiple neurological diseases, is currently in IND-enabling studies with IND application submission to the FDA expected in the fourth quarter of 2022.
  • In March 2022, Dr. Randall Kaye joined the Company as Chief Medical Officer.
  • First Quarter 2022 Financial Results:
    At March 31, 2022, Longboards cash, cash equivalents and short-term investments were approximately $96.1 million.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Virpax Successfully Completes Initial Preclinical Studies for VRP324

Retrieved on: 
Tuesday, April 26, 2022

In this preclinical PK study, VRP324 was able to deliver cannabidiol (CBD) to the brain after nasal administration in a rodent model.

Key Points: 
  • In this preclinical PK study, VRP324 was able to deliver cannabidiol (CBD) to the brain after nasal administration in a rodent model.
  • Nasal delivery of VRP324 provided high concentrations of CBD in the brain and the preclinical studies confirm that there were higher levels of CBD in the brain versus the plasma.
  • VRP324 uses a preassembled device and cartridge to propel the MET-CBD powder formulation into the nose via the olfactory nerve/bulb.
  • Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.

Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8:00 a.m. ET

Retrieved on: 
Monday, April 18, 2022

Management will host a conference call for investors at 8:00 a.m.

Key Points: 
  • Management will host a conference call for investors at 8:00 a.m.
  • The conference call can be accessed by dialing (866) 417-5886 from the U.S. and (409) 217-8235 internationally, followed by the conference ID: 8453318.
  • There will also be a simultaneous, live webcast available on the Investors section of the Companys website at https://investors.aquestive.com/events-and-presentations .
  • PharmFilm, Sympazan and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital

Retrieved on: 
Wednesday, April 13, 2022

Aquestivemay terminate the purchase agreement at any time, at its sole discretion, without any cost or penalty.

Key Points: 
  • Aquestivemay terminate the purchase agreement at any time, at its sole discretion, without any cost or penalty.
  • Aquestiveintends to use the net proceeds from the sale of its common stock under the purchase agreement for working capital and general corporate purposes to support its growth.
  • We are pleased to enter into this agreement with Lincoln Park Capital, as it represents an important potential source of capital available to the Company, said Keith Kendall, Chief Executive Officer of Aquestive.
  • The shares of common stock covered by the purchase agreement are being offered pursuant to a shelf registration statement (File No.

Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

Retrieved on: 
Tuesday, April 12, 2022

I look forward to further evaluation of this investigational medicine in the next phase of the EPIPHAST study.

Key Points: 
  • I look forward to further evaluation of this investigational medicine in the next phase of the EPIPHAST study.
  • EPIPHAST is a randomized, open-label, three-part adaptive design, crossover study in healthy adult subjects comparing the pharmacokinetics and pharmacodynamics of epinephrine delivered via Aquestives AQST-109 oral film compared to intramuscular injection of epinephrine.
  • AQST-109 is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine.
  • PharmFilm, Sympazan and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.